XML 26 R38.htm IDEA: XBRL DOCUMENT v3.20.1
INVESTMENTS (Details Narrative)
 1 Months Ended 3 Months Ended 12 Months Ended
Mar. 23, 2020
USD ($)
Feb. 25, 2020
USD ($)
Jan. 27, 2020
USD ($)
Jul. 16, 2018
USD ($)
shares
Mar. 31, 2020
USD ($)
$ / shares
shares
Mar. 31, 2020
EUR (€)
Mar. 31, 2020
CAD ($)
Dec. 31, 2018
Dec. 31, 2019
USD ($)
Jun. 30, 2019
May 17, 2018
shares
Net unrealized loss on fair value investment         $ 3,272            
Marathon Global Inc [Member]                      
Gain on exchange of investment         1,953,000            
Kaneh Bosm Biotechnology Inc [Member] | Share Exchange Agreement [Member]                      
Transfer of shares | shares                     2,500,000
Kaneh Bosm Biotechnology Inc [Member] | Share Exchange Agreement [Member] | Canadian Securities Exchange [Member]                      
Exchange of shares | shares                     5,000,000
Share exchange agreement [Member] | ICC [Member]                      
Net unrealized loss on fair value investment         18,900            
Investement         $ 14,100       $ 33,000    
Equity method investment shares acquired | shares       5,000,000              
Description for ownership percentage       The ten million shares of ICC owned by the Company constituted approximately 7% of the 141,219,108 shares of capital stock of KBB then issued and outstanding. The Company does not have the ability to exercise significant influence over ICC              
Additional shares issued | shares         3,000,000            
Share exchange agreement [Member] | Marathon Global Inc [Member]                      
Shares of Marathon transferred by company to KBB | shares       2,500,000              
Gain on exchange of investment       $ 2,092,200              
Distribution and Equity Acquisition Agreement [Member] | Marathon Global Inc [Member]                      
Equity interest acquired description         a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services      
Cash received upon repayment for purchase common stock             $ 2,000,000        
Distribution and Equity Acquisition Agreement [Member] | Marathon Global Inc [Member] | Gross Sales One [Member]                      
Cash received upon gross sales       2,750,000        
Gross sales             13,000,000        
Distribution and Equity Acquisition Agreement [Member] | Marathon Global Inc [Member] | Gross Sales [Member]                      
Cash received upon gross sales             2,750,000        
Gross sales             $ 6,500,000        
Marketable securities - Divsersa S.A. [Member]                      
Closing price of shares | $ / shares         $ 4.91            
Shares issued as marketable securities | shares         40,000            
Marketable securities - National Bank of Greece [Member]                      
Closing price of shares | $ / shares         $ 0.33            
Marketable securities         $ 2,275            
Shares issued as marketable securities | shares         16,666            
Cosmo Farmacy LP [Member]                      
Investement         $ 165,195            
Initial share capital | €           € 150,000          
Initial share capital increased | €           500,000          
Pharmacy license value | €           € 350,000          
Maturity period of license         30 years 30 years 30 years        
Ownership equity                   70.00%  
cash contributed to limited partner | €           € 150,000          
Equity ownership remaining                   30.00%